Nautilus Biotechnology Reports Q2 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%

Reuters

2025/07/31

Nautilus Biotechnology Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%

Nautilus Biotechnology Inc. $(NAUT)$ reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9503747-en) on July 31, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555038880"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555038880\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555038880?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555038880","market":"nz","top_or_hot":-1,"title":"Nautilus Biotechnology Reports Q2 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nautilus Biotechnology Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nautilus Biotechnology Inc. <a href=\"https://laohu8.com/S/NAUT\">$(NAUT)$</a> reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9503747-en) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nautilus Biotechnology Reports Q2 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNautilus Biotechnology Reports Q2 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nautilus Biotechnology Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nautilus Biotechnology Inc. <a href=\"https://laohu8.com/S/NAUT\">$(NAUT)$</a> reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9503747-en) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL7Vptf5:1","article_id":"2555038880","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555038880","pubTimestamp":1753963281,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nautilus Biotechnology Inc.  reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.Disclaimer: This news brief was created by Public Technologies  using ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","NAUT":"Nautilus Biotechnolgy, Inc."},"translate_title":"Nautilus Biotechnology报告2025年第二季度业绩：净亏损收窄至1500万美元，运营费用下降18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NAUT":0.9},"content_text":"Nautilus Biotechnology Reports Q2 2025 Results: Net Loss Narrows to $15M, Operating Expenses Down 18%\n    \n\n        Nautilus Biotechnology Inc. $(NAUT)$ reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9503747-en) on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}